Article
4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes. A case series at 2 centers
2024-11-08
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Introduction</h4> Pathogenic mutations in STXBP1 and SLC6A1 can cause developmental delay and epilepsy. 4-phenylbutyrate (4PB), a drug used for urea cycle disorders, rescues dysfunction in pre-clinical models for both genes, suggesting an opportunity for drug repurposing. <h4>Methods</h4> We conducted a single-treatment group, multiple-dose, open-label study of 4PB (as glycerol phenylbutyr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 36f932c7-3731-5a04-bace-cf8ff021cd6e
- DOI
- 10.1101/2024.11.06.24316676
